Clinical Trial Update: Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial update on Omegaven for parenteral nutrition-associated liver disease has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parenteral Nutrition-related Hepatitis

Drugs mentioned

• Omegaven (fish oil-based intravenous fat emulsion)

Snippet

Sponsor: Children's Mercy Hospital Kansas City | Conditions: Parenteral Nutrition-related Hepatitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-03-12